Application of mesenchymal stem cell paracrine factor in eye drops

A kind of stem cell and paracrine technology, applied in the field of biological stem cell technology in the field of ophthalmology, can solve the problems of non-discovery, permanent blindness, difficulty, etc., and achieve the effects of improving vision, reducing local inflammatory response and degeneration, and being easy to prepare.

Inactive Publication Date: 2019-11-12
北京中广天一生物科技有限公司
View PDF1 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Macular degeneration, if left untreated, can lead to permanent blindness
At present, in modern medicine, there is no definite drug

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mesenchymal stem cell paracrine factor in eye drops
  • Application of mesenchymal stem cell paracrine factor in eye drops

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0049] Example 1 Preparation of Umbilical Cord Mesenchymal Stem Cell Paracrine Factor Eye Drops

[0050] The umbilical cord mesenchymal stem cell eye drops of the present invention are mainly derived from human umbilical cord mesenchymal stem cells, but the source of stem cells is not limited to the umbilical cord, and can be derived from multiple human tissue sources such as human placenta, bone marrow, dental pulp, and fat.

[0051] Wherein, the preparation process of umbilical cord mesenchymal stem cell paracrine factor eye drops is as follows:

[0052] (1) Cultivation of umbilical cord mesenchymal stem cells: cut fresh umbilical cord, wash it with sterile saline, further remove visible blood vessels, cut the umbilical cord to a small tissue piece about 2-3cm in size, and put it into a cell culture dish Middle, cut the umbilical cord Wharton's jelly: cut the washed umbilical cord Wharton's jelly into 1-3mm tissue fragments, and centrifuge; remove the supernatant from the ce...

Embodiment 2

[0055] Example 2 Ocular Safety Evaluation Test of Mesenchymal Stem Cell Paracrine Factor Eye Drops:

[0056] Randomly select 24 healthy SD rats of any sex and divide them into two groups: one group is used as blank control, the left eye is not treated, and the right eye is given medical saline; the other group is used as the experimental group, the left eye is not treated, and the right eye is given this Invented umbilical cord mesenchymal stem cell paracrine factor eye drops. 3 times a day, 1-2 drops (about 200μl / drop) at a time, continuous eye drops for 14 days. During this period, two time points of 7 days and 14 days were selected to observe the physiological changes of the rats. According to the Draize scoring standard, the performance of rat eyes was scored for irritation. No irritation is 0-3 points; mild stimulation is 4-8 points; moderate stimulation is 9-12 points; severe stimulation is 13-16 points. The final results showed that instillation of normal saline and ...

Embodiment 3

[0057] Example 3 Human eye safety evaluation test of mesenchymal stem cell paracrine factor eye drops:

[0058] Randomly select 30 volunteers (regardless of gender) with single-eye point umbilical cord mesenchymal stem cell paracrine factor eye drops. 3 times a day, 1-2 drops (about 300μl / drop) at a time, continuous eye drops for 14 days. During the period, two time points of 7 days and 14 days were selected for visual acuity test, fundus test, blood routine test and biochemical test. The final results showed that the volunteers did not see eye redness and swelling, increased eye secretions or any other discomfort at the two time points of 7 days and 14 days after dripping mesenchymal stem cell exosome eye drops. At the same time, no abnormalities were found in the fundus examination , Blood routine and biochemical tests were normal. After three months and half a year, 30 volunteers were re-examined, and all symptoms and blood indicators were normal. The above fully shows t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a mesenchymal stem cell paracrine factor in eye drops, relates to an application of biological stem cell technology field in ophthalmology, and particularly relates to an application of the mesenchymal stem cell paracrine factor in the preparation of eye drops for macular degeneration of retina. A mesenchymal stem cell source for obtaining the paracrine factor includes umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, umbilical cord blood mesenchymal stem cells, adipose mesenchymal stem cells, placental mesenchymal stem cells,amniotic membrane mesenchymal stem cells and other mesenchymal stem cells from various tissues of all mammals, especially humans. The components of the eye drops are all mesenchymal stem cell paracrine factors, and the protein is cryopreserved to maintain the protein activity to the greatest extent.

Description

technical field [0001] The invention relates to the application of biological stem cell technology in ophthalmology, in particular to a preparation method and application of eye drops for treating macular degeneration of retina. Background technique [0002] Macular degeneration of the retina is a decrease in the ability of the retinal pigment epithelial cells to phagocytize and digest the outer segmental disc membrane of the visual cell. membrane, forming drusen. Due to the special structure and function of the macula, this change is more obvious. Drusen is also seen in the elderly with normal vision, but after various pathological changes secondary to it, it leads to macular degeneration. Most of the disease occurs in people over 45 years old, and its prevalence rate increases with age. It is an important disease that causes blindness in the elderly. If left untreated, macular degeneration can lead to permanent blindness. At present, in modern medicine, there is no def...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/08A61K38/17A61K35/28A61P27/02
CPCA61K9/0048A61K9/08A61K35/28A61K38/1709A61P27/02
Inventor 刘学彬张成城
Owner 北京中广天一生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap